Published in J Virol on February 10, 2010
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med (2014) 2.82
Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov (2015) 1.47
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol (2012) 1.28
Vesicular stomatitis virus as a treatment for colorectal cancer. Cancer Gene Ther (2011) 0.89
Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection. Cancer Gene Ther (2014) 0.88
Experimental infection of mice with avian paramyxovirus serotypes 1 to 9. PLoS One (2011) 0.87
Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host. Biology (Basel) (2013) 0.86
Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma. J Surg Res (2013) 0.84
Cell-type-specific innate immune response to oncolytic Newcastle disease virus. Viral Immunol (2012) 0.83
Attenuation of mouse hepatitis virus by deletion of the LLRKxGxKG region of Nsp1. PLoS One (2013) 0.83
Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy. J Virol (2013) 0.81
The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-β signaling. J Interferon Cytokine Res (2013) 0.80
Recombinant Newcastle disease virus (rL-RVG) triggers autophagy and apoptosis in gastric carcinoma cells by inducing ER stress. Am J Cancer Res (2016) 0.79
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy. J Virol (2016) 0.77
Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines. J Virol (2014) 0.76
Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer. Virol J (2014) 0.76
Proinflammatory response induced by Newcastle disease virus in tumor and normal cells. Oncolytic Virother (2017) 0.75
Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma. Viruses (2015) 0.75
Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists. Vaccines (Basel) (2016) 0.75
Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. Stem Cell Res Ther (2016) 0.75
Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic Virother (2015) 0.75
How cells respond to interferons. Annu Rev Biochem (1998) 24.27
IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature (2005) 13.23
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
pppA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc Natl Acad Sci U S A (1978) 5.69
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med (2000) 4.37
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett (1998) 3.80
PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol (2006) 3.13
Regulation of the type I IFN induction: a current view. Int Immunol (2005) 2.82
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41
Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology (2000) 2.39
A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol (2000) 1.92
Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther (2005) 1.85
The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence. J Virol (2004) 1.79
Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J Virol (2003) 1.73
Transcriptional regulation of interferon-stimulated genes. Eur J Biochem (1991) 1.61
Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res (2007) 1.53
Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst (1994) 1.47
Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol (2006) 1.44
A bipartite model of 2-5A-dependent RNase L. J Biol Chem (1997) 1.42
Newcastle disease virus selectively kills human tumor cells. J Surg Res (1992) 1.40
Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol (2006) 1.37
High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc Natl Acad Sci U S A (2001) 1.32
Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J Natl Cancer Inst (1988) 1.20
Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res (1994) 1.16
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther (2003) 1.15
Bcr-Abl variants: biological and clinical aspects. Leuk Res (2002) 1.11
Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett (2001) 1.11
Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer (2006) 1.08
Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther (2009) 1.04
Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer (1994) 1.04
Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther (2002) 0.99
A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother (1992) 0.98
Characterization of a battery of monoclonal antibodies for differentiation of Newcastle disease virus and pigeon paramyxovirus-1 strains. Avian Dis (1988) 0.94
Viruses in the treatment of cancer. Lancet (1971) 0.90
Interferon production in mouse spleen cells and mouse fibroblasts (L cells) stimulated by various strains of Newcastle disease virus. J Gen Virol (1982) 0.88
Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Cancer Gene Ther (2007) 0.87
Refolding and structural characterization of the human p53 tumor suppressor protein. Biophys Chem (2002) 0.86
Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein. Int J Oncol (2005) 0.85
The cytotoxic anti-tumor effect of MTH-68/H, a live attenuated Newcastle disease virus is mediated by the induction of nitric oxide synthesis in rat peritoneal macrophages in vitro. Cancer Lett (2006) 0.85
Dissociation between IFN-alpha-induced anti-viral and growth signaling pathways. J Immunol (1999) 0.83
Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: predictors and clinical relevance. Biol Blood Marrow Transplant (2002) 0.82
Viruses for the treatment of malignant glioma. Curr Opin Mol Ther (2001) 0.82
Effect of liposomal tetracycline hydrochloride on enzymatic function of the liver. Bull Exp Biol Med (2008) 0.77
Loss of heterozygosity among tumor suppressor genes in invasive and in situ carcinoma of the uterine cervix. Int J Gynecol Cancer (2000) 0.77
Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microb Pathog (2004) 3.14
The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence. J Virol (2004) 1.79
Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J Virol (2003) 1.73
Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol (2005) 1.72
Complete genome sequence of avian paramyxovirus type 3 reveals an unusually long trailer region. Virus Res (2008) 1.63
Molecular characterization and complete genome sequence of avian paramyxovirus type 4 prototype strain duck/Hong Kong/D3/75. Virol J (2008) 1.50
A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. J Virol (2004) 1.41
Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A (2007) 1.39
Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol (2006) 1.37
Chlorpyrifos affects phenotypic outcomes in a model of mammalian neurodevelopment: critical stages targeting differentiation in PC12 cells. Environ Health Perspect (2006) 1.37
Complete genome sequence of avian paramyxovirus type 7 (strain Tennessee) and comparison with other paramyxoviruses. Virus Res (2009) 1.36
Complete genome sequence of avian paramyxovirus (APMV) serotype 5 completes the analysis of nine APMV serotypes and reveals the longest APMV genome. PLoS One (2010) 1.31
Complete genome sequence of a novel Newcastle disease virus strain isolated from a chicken in West Africa. J Virol (2012) 1.30
Complete genome sequences of avian paramyxovirus type 8 strains goose/Delaware/1053/76 and pintail/Wakuya/20/78. Virus Res (2009) 1.30
Complete genome sequences of avian paramyxovirus serotype 6 prototype strain Hong Kong and a recent novel strain from Italy: evidence for the existence of subgroups within the serotype. Virus Res (2010) 1.29
Behavioral alterations in adolescent and adult rats caused by a brief subtoxic exposure to chlorpyrifos during neurulation. Neurotoxicol Teratol (2004) 1.27
Complete sequence of the genome of avian paramyxovirus type 2 (strain Yucaipa) and comparison with other paramyxoviruses. Virus Res (2008) 1.27
Roles of the fusion and hemagglutinin-neuraminidase proteins in replication, tropism, and pathogenicity of avian paramyxoviruses. J Virol (2011) 1.23
Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine (2010) 1.20
Complete sequence of the genome of avian paramyxovirus type 9 and comparison with other paramyxoviruses. Virus Res (2009) 1.20
The large polymerase protein is associated with the virulence of Newcastle disease virus. J Virol (2008) 1.20
Complete genome sequences of Newcastle disease virus strains circulating in chicken populations of Indonesia. J Virol (2012) 1.18
Role of intergenic sequences in newcastle disease virus RNA transcription and pathogenesis. J Virol (2007) 1.15
Short-term adolescent nicotine exposure has immediate and persistent effects on cholinergic systems: critical periods, patterns of exposure, dose thresholds. Neuropsychopharmacology (2003) 1.15
Biological significance of the second receptor binding site of Newcastle disease virus hemagglutinin-neuraminidase protein. J Virol (2004) 1.13
Effects of prenatal nicotine exposure on primate brain development and attempted amelioration with supplemental choline or vitamin C: neurotransmitter receptors, cell signaling and cell development biomarkers in fetal brain regions of rhesus monkeys. Neuropsychopharmacology (2005) 1.12
Induction of type I interferons by a novel porcine reproductive and respiratory syndrome virus isolate. Virology (2012) 1.11
Chlorpyrifos targets developing glia: effects on glial fibrillary acidic protein. Brain Res Dev Brain Res (2002) 1.10
Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J Virol (2009) 1.08
Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses. PLoS One (2009) 1.08
Loss of N-linked glycosylation from the hemagglutinin-neuraminidase protein alters virulence of Newcastle disease virus. J Virol (2004) 1.06
Role of untranslated regions of the hemagglutinin-neuraminidase gene in replication and pathogenicity of newcastle disease virus. J Virol (2009) 1.06
Complete genome sequence of highly virulent neurotropic Newcastle disease virus strain Texas GB. Virus Genes (2010) 1.03
Phylogenetic and pathotypic characterization of newcastle disease viruses circulating in west Africa and efficacy of a current vaccine. J Clin Microbiol (2012) 1.01
Adverse neurodevelopmental effects of dexamethasone modeled in PC12 cells: identifying the critical stages and concentration thresholds for the targeting of cell acquisition, differentiation and viability. Neuropsychopharmacology (2005) 1.00
A single amino acid change, Q114R, in the cleavage-site sequence of Newcastle disease virus fusion protein attenuates viral replication and pathogenicity. J Gen Virol (2011) 1.00
Generation by reverse genetics of an effective, stable, live-attenuated newcastle disease virus vaccine based on a currently circulating, highly virulent Indonesian strain. PLoS One (2012) 1.00
Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans. Vaccine (2009) 0.99
Replication, neurotropism, and pathogenicity of avian paramyxovirus serotypes 1-9 in chickens and ducks. PLoS One (2012) 0.96
Evaluation of the Newcastle disease virus F and HN proteins in protective immunity by using a recombinant avian paramyxovirus type 3 vector in chickens. J Virol (2011) 0.96
A Y526Q mutation in the Newcastle disease virus HN protein reduces its functional activities and attenuates virus replication and pathogenicity. J Virol (2009) 0.95
The MHC class II-associated invariant chain interacts with the neonatal Fc gamma receptor and modulates its trafficking to endosomal/lysosomal compartments. J Immunol (2008) 0.94
Complete genome sequence of avian paramyxovirus-3 strain Wisconsin: evidence for the existence of subgroups within the serotype. Virus Res (2010) 0.93
Complete genome sequence of a virulent Newcastle disease virus isolated from an outbreak in chickens in Egypt. Virus Genes (2009) 0.93
Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. J Virol (2011) 0.92
Mutations in the fusion protein cleavage site of avian paramyxovirus serotype 2 increase cleavability and syncytium formation but do not increase viral virulence in chickens. J Virol (2011) 0.92
Does pharmacotherapy for preterm labor sensitize the developing brain to environmental neurotoxicants? Cellular and synaptic effects of sequential exposure to terbutaline and chlorpyrifos in neonatal rats. Toxicol Appl Pharmacol (2004) 0.92
Avian paramyxovirus serotypes 2-9 (APMV-2-9) vary in the ability to induce protective immunity in chickens against challenge with virulent Newcastle disease virus (APMV-1). Vaccine (2012) 0.92
Prediction of disease and phenotype associations from genome-wide association studies. PLoS One (2011) 0.92
Evaluation of the genetic diversity of avian paramyxovirus type 4. Virus Res (2012) 0.91
Complete genome sequence of an avian paramyxovirus type 4 from north america reveals a shorter genome and new genotype. Genome Announc (2013) 0.90
The pathogenesis of Newcastle disease: a comparison of selected Newcastle disease virus wild-type strains and their infectious clones. Virology (2006) 0.90
Modeling the developmental neurotoxicity of nicotine in vitro: cell acquisition, growth and viability in PC12 cells. Brain Res Dev Brain Res (2005) 0.89
Newcastle disease virus fusion protein is the major contributor to protective immunity of genotype-matched vaccine. PLoS One (2013) 0.88
Complete sequence of the G glycoprotein gene of avian metapneumovirus subgroup C and identification of a divergent domain in the predicted protein. J Gen Virol (2004) 0.88
A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen. Vaccine (2011) 0.88
Deduced amino acid sequence of the small hydrophobic protein of US avian pneumovirus has greater identity with that of human metapneumovirus than those of non-US avian pneumoviruses. Virus Res (2003) 0.88
Experimental infection of mice with avian paramyxovirus serotypes 1 to 9. PLoS One (2011) 0.87
Recovery of avian metapneumovirus subgroup C from cDNA: cross-recognition of avian and human metapneumovirus support proteins. J Virol (2006) 0.86
Sequence analysis of fusion protein gene of Newcastle disease virus isolated from outbreaks in Egypt during 2006. Virol J (2011) 0.86
Complete genome sequences of avian paramyxovirus serotype 2 (APMV-2) strains Bangor, England and Kenya: evidence for the existence of subgroups within serotype 2. Virus Res (2010) 0.86
Identification of Mycobacterium tuberculosis-specific Th1, Th17 and Th22 cells using the expression of CD40L in tuberculous pleurisy. PLoS One (2011) 0.86
B lymphocytes that migrate to tuberculous pleural fluid via the SDF-1/CXCR4 axis actively respond to antigens specific for Mycobacterium tuberculosis. Eur J Immunol (2011) 0.86
Distinct polyfunctional CD4+ T cell responses to BCG, ESAT-6 and CFP-10 in tuberculous pleurisy. Tuberculosis (Edinb) (2011) 0.86
Experimental avian paramyxovirus serotype-3 infection in chickens and turkeys. Vet Res (2010) 0.85
Role of untranslated regions in regulation of gene expression, replication, and pathogenicity of Newcastle disease virus expressing green fluorescent protein. J Virol (2009) 0.85
Reversible 3-Li storage reactions of amorphous phosphorus as high capacity and cycling-stable anodes for Li-ion batteries. Chem Commun (Camb) (2012) 0.85
The immune responses of central and effector memory BCG-specific CD4+ T cells in BCG-vaccinated PPD+ donors were modulated by Treg cells. Immunobiology (2010) 0.85
The interferon antagonistic activities of the V proteins from two strains of Newcastle disease virus correlate with their known virulence properties. Virus Res (2009) 0.84
Identification of simian agent 10 as human parainfluenza virus type 3 suggests transmission of a human virus to an African monkey. J Virol (2010) 0.84
Processing enzyme glucosidase II: proposed catalytic residues and developmental regulation during the ontogeny of the mouse mammary gland. Glycobiology (2004) 0.84
Mutations in the cytoplasmic domain of the Newcastle disease virus fusion protein confer hyperfusogenic phenotypes modulating viral replication and pathogenicity. J Virol (2013) 0.83
Identification of M. tuberculosis-specific Th1 cells expressing CD69 generated in vivo in pleural fluid cells from patients with tuberculous pleurisy. PLoS One (2011) 0.83
Cell-type-specific innate immune response to oncolytic Newcastle disease virus. Viral Immunol (2012) 0.83
Pleural fluid from tuberculous pleurisy inhibits the functions of T cells and the differentiation of Th1 cells via immunosuppressive factors. Cell Mol Immunol (2011) 0.83
Pathogenesis of two strains of avian paramyxovirus serotype 2, Yucaipa and Bangor, in chickens and turkeys. Avian Dis (2010) 0.82
Genetic characterization of swine influenza viruses (H3N2) isolated from Minnesota in 2006-2007. Virus Genes (2011) 0.82
Sequence analysis of the large polymerase (L) protein of the US strain of avian metapneumovirus indicates a close resemblance to that of the human metapneumovirus. Virus Res (2004) 0.81
Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy. J Virol (2013) 0.81
Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector. PLoS One (2013) 0.81
Role of the cytoplasmic tail amino acid sequences of Newcastle disease virus hemagglutinin-neuraminidase protein in virion incorporation, cell fusion, and pathogenicity. J Virol (2009) 0.81
Experimental infection of hamsters with avian paramyxovirus serotypes 1 to 9. Vet Res (2011) 0.80
Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus. Hum Vaccin Immunother (2015) 0.79
Calcitonin gene-related peptide inhibits osteolytic factors induced by osteoblast in co-culture system with breast cancer. Cell Biochem Biophys (2014) 0.79
Contribution of the attachment G glycoprotein to pathogenicity and immunogenicity of avian metapneumovirus subgroup C. Avian Dis (2010) 0.78
Developmental toxicity of terbutaline: critical periods for sex-selective effects on macromolecules and DNA synthesis in rat brain, heart, and liver. Brain Res Bull (2003) 0.78
Analysis of the complete genome sequence of avian metapneumovirus subgroup C indicates that it possesses the longest genome among metapneumoviruses. Virus Genes (2005) 0.78
Experimental infection of calves with Newcastle disease virus induces systemic and mucosal antibody responses. Arch Virol (2008) 0.78
Inhibition of host innate immune responses and pathogenicity of recombinant Newcastle disease viruses expressing NS1 genes of influenza A viruses. J Gen Virol (2010) 0.77
[Cytokine production and clonal analysis of memory γδ T cells from patients with tuberculous pleurisy induced by bacille calmette guerin]. Zhonghua Jie He He Hu Xi Za Zhi (2010) 0.77
Complete genome sequence of a highly virulent newcastle disease virus currently circulating in Mexico. Genome Announc (2013) 0.77
Evaluation of the replication, pathogenicity, and immunogenicity of avian paramyxovirus (APMV) serotypes 2, 3, 4, 5, 7, and 9 in rhesus macaques. PLoS One (2013) 0.77